Collagenase clostridium histolyticum
Xiapex (collagenase clostridium histolyticum or CCH) is the first pharmacological treatment approved in the EU for the treatment of Dupuytren’s contracture in adult patients with a palpable cord.1
The treatment involves injecting Xiapex into the Dupuytren’s cord. Xiapex uses a precise enzymatic action that dissolves collagen in the cord.1
Xiapex is a non-surgical approach that uses enzymes (a mixture of Class I (AUX-I) and Class II (AUX-II) clostridial collagenases) injected directly into the affected rope-like cord under the skin. Together, these collagenases work to digest collagen in the cord which is mainly comprised of interstitial collagen types I and III.1
The injection is followed by a procedure approximately after 24-72 hours during which the finger is extended by the doctor, breaking the cord.1 In some cases, the cord breaks on its own so the extension procedure is not needed.
This treatment does not require the patient to stay in hospital. Anaesthetic is not needed for the injection, although local anaesthetic may be used for the extension procedure.1
- Xiapex Summary of Product Characteristics.